Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion studyUdai Banerji, Philippe Aftimos, Carla M.L. van Herpen et al.|The Lancet Oncology|2019Cited by 564
Integrated Pharmacodynamic Analysis Identifies Two Metabolic Adaption Pathways to Metformin in Breast CancerSimon Lord, Adrian L. Harris|Cell Metabolism|2018Cited by 127
Heritable genetic variants in key cancer genes link cancer risk with anthropometric traitsMatteo Di Giovannantonio, Gareth L. Bond, Natasha Sahgal et al.|Journal of Medical Genetics|2020Cited by 18
Cancer Precision-Prevention trial of Metformin in adults with Li Fraumeni syndrome (MILI) undergoing yearly MRI surveillance: a randomised controlled trial protocolMiriam Dixon-Zegeye, Sarah P. Blagden, Rachel Shaw et al.|Trials|2024Cited by 15
A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301)Pavlina Spiliopoulou, Sarah P. Blagden, Farasat Kazmi et al.|Journal of Experimental & Clinical Cancer Research|2024Cited by 8